Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator-Reference-Cited by-同舟云学术

Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator

Published:2021-05 Issue:5 Volume:10 Page:441-454
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Wang Kun¹,Yao Xueting²,Zhang Miao²,Liu Dongyang²,Gao Yuying¹,Sahasranaman Srikumar³,Ou Ying C.³

Affiliation:

1. Shanghai Qiangshi Information Technology Co., Ltd Shanghai China

2. Drug Clinical Trial Center Peking University Third Hospital Beijing China

3. BeiGene USA, Inc San Mateo CA USA

Publisher

Wiley

Subject

Pharmacology (medical),Modelling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12605

Reference39 articles.

1. Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase

2. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

3. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

4. Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects

5. Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P‐gp and BCRP;Ou YC;Br J Clin Pharmacol,2020

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia;Expert Review of Hematology;2024-08-21

2. Physiologically Based Pharmacokinetic Modeling of the Drug–Drug Interaction Between CYP3A4 Substrate Glasdegib and Moderate CYP3A4 Inducers in Lieu of a Clinical Study;The Journal of Clinical Pharmacology;2023-10-18

3. Drug-drug interactions and dose management of BTK inhibitors when initiating nirmatrelvir/ritonavir (paxlovid) based on physiologically-based pharmacokinetic models;European Journal of Pharmaceutical Sciences;2023-10

4. Application of physiologically based pharmacokinetics modeling in the research of small-molecule targeted anti-cancer drugs;Cancer Chemotherapy and Pharmacology;2023-07-19

5. Bruton's tyrosine kinase inhibitors and their current status in the treatment of chronic lymphocytic leukemia;Onkologie;2023-06-16